Search Results

You are looking at 1 - 10 of 118 items for :

  • "Aromatase inhibitors" x
  • Refine by Access: All x
Clear All
Full access

John Charlson, Elizabeth C. Smith, Alicia J. Smallwood, Purushottam W. Laud, and Joan M. Neuner

Background Aromatase inhibitors (AIs), tamoxifen, and the sequential use of these agents are all standard options for adjuvant hormonal therapy (HT) for postmenopausal women with early-stage, estrogen receptor (ER)–positive breast cancer. At

Full access

Tiffany H. Svahn, Joyce C. Niland, Robert W. Carlson, Melissa E. Hughes, Rebecca A. Ottesen, Richard L. Theriault, Stephen B. Edge, Anne F. Schott, Michael A. Bookman, and Jane C. Weeks

in longitudinal studies: development and validation . J Chronic Dis 1987 ; 40 : 373 – 383 . 14 Winer EP Hudis C Burstein HJ . American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant

Full access

Alyssa G. Rieber and Richard L. Theriault

: 1451 – 1467 . 4 Smith IE . Drug therapy: aromatase inhibitors in breast cancer . N Engl J Med 2003 ; 348 : 2431 – 2442 . 5 Kaufmann M Bajetta E Dirix LY . Exemestane is superior to megestrol acetate after tamoxifen failure in

Full access

Jennifer A. Ligibel and Eric P. Winer

Anderson E : New endocrine therapies for breast cancer . Eur J Cancer 1996 ; 32A : 576 – 588 . 8 Goss P Starasser K . Aromatase inhibitors in the treatment and prevention of breast cancer . J Clin Oncol 2001 ; 19 : 881 – 894 . 9

Full access

Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond, and Mark S. Carey

of an aromatase inhibitor (AI; letrozole) for 5 years significantly reduced recurrences and mortality compared with placebo after 5 years of initial tamoxifen, 3 and this effect was greater in premenopausal compared with postmenopausal women. 4 No

Full access

John A. Charlson, Emily L. McGinley, Ann B. Nattinger, Joan M. Neuner, and Liliana E. Pezzin

initially demonstrated in the mid-1980s, 3 or an aromatase inhibitor (AI). Beginning in 2005, recommendations from ASCO suggested that adjuvant therapy for postmenopausal women with HR+ breast cancer include an AI, either alone or in sequence after

Full access

Ingrid A. Mayer

, aromatase inhibitor; ET, endocrine therapy, MBC, metastatic breast cancer. therapy–resistant tumors. In de novo resistance, loss of estrogen receptors (ER) or loss of amplification of co-receptors and co-amplifiers, as well as activation of the cyclin

Full access

Amelia B. Zelnak and Ruth M. O'Regan

analysis of SOFT and TEXT, an aromatase inhibitor (AI) plus ovarian suppression represents a new option for patients. Multiple questions remain, such as the timing of ovarian suppression with chemotherapy (concurrently, as on TEXT vs sequentially, as on

Full access

Rodrigo Goncalves and Ron Bose

subtype breast cancers, a statistically significant difference ( P =.02) is seen in the number of point mutations between cancers that are aromatase inhibitor (AI)–sensitive and AI-resistant. 33 Figure 3A shows a genome wheel in which the 23 chromosomes

Full access

Robert W. Carlson, Clifford A. Hudis, and Kathy I. Pritchard

. 27. Winer EP Hudis C Burstein HJ . American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002 . J Clin Oncol